nach oben

Archives of Virology

Erschienen in:

01.04.2023 | Original Article

An oncolytic herpes simplex virus type 1 strain expressing a single-chain variable region antibody fragment against PD-1 and a PI3K inhibitor synergize to elicit antitumor immunity in ovarian cancer

verfasst von: Shanying Huang, Haiyan Hu, Guoling Tang, Kai Liu, Zhihua Luo, Weiwei Zeng

Erschienen in: Archives of Virology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Due to recurrence and resistance to chemotherapy, the current standard therapeutics are not fully effective against ovarian cancer. Therefore, we aimed to find an effective approach to improve the prognosis and therapy of ovarian cancer. NG34ScFvPD-1 is a modified oncolytic herpes simplex virus NG34 strain that expresses a single-chain antibody against programmed cell death protein 1 (PD-1) (ScFvPD-1). We assessed its efficacy and its regulatory mechanism in a mouse model of ovarian cancer. Enzyme-linked immunosorbent assay and western blot techniques were used to measure protein expression. Oncolysis caused by NG34ScFvPD-1 was examined using cytotoxicity and replication assays. The mechanism by which NG34ScFvPD-1 regulates apoptosis of ovarian cancer cells in vitro was also evaluated. We assessed the antitumor immunity and therapeutic potency of NG34ScFvPD-1 in combination with a phosphoinositide 3-kinase (PI3K) inhibitor. We found that NG34ScFvPD-1-infected ovarian cancer cells expressed and secreted ScFvPD-1, which bound mouse PD-1. The insertion of the ScFvPD-1 sequence did not inhibit the oncolytic activity of NG34ScFvPD-1, which induced apoptosis of ovarian cancer cells via the caspase-dependent pathway in vitro and activated the PI3K/AKT signaling pathway. Synergy was observed between NG34ScFvPD-1 and a PI3K inhibitor, and the combination was able to suppress tumor development, to prolong survival, and to elicit potent antitumor immunity. Thus, inhibition of PI3K enhanced the potent antitumor immunity induced by NG34ScFvPD-1 against ovarian cancer.

Nur mit Berechtigung zugänglich

Bartee MY, Dunlap KM, Bartee E (2017) Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy. Cancer Res 77:2952–2963CrossRefPubMedPubMedCentral

Bommareddy PK, Shettigar M, Kaufman HL (2018) Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol 18:498–513CrossRefPubMed

Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A, Bhat T, Ghumman F, Sheriff M, Pavlidis N (2020) Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. Drugs R D 20:55–73CrossRefPubMedPubMedCentral

Cao GD, He XB, Sun Q, Chen S, Wan K, Xu X, Feng X, Li PP, Chen B, Xiong MM (2020) The Oncolytic Virus in Cancer Diagnosis and Treatment. Front Oncol 10:1786CrossRefPubMedPubMedCentral

Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umansky V, Nettelbeck DM, Weichert W, Jäger D, von Kalle C, Ungerechts G (2014) CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 22:1949–1959CrossRefPubMedPubMedCentral

Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL (2017) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545:495–499CrossRefPubMedPubMedCentral

Havel JJ, Chowell D, Chan TA (2019) The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer 19:133–150CrossRefPubMedPubMedCentral

Hutzen B, Chen CY, Wang PY, Sprague L, Swain HM, Love J, Conner J, Boon L, Cripe TP (2017) TGF-beta Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma. Mol Ther Oncolytics 7:17–26CrossRefPubMedPubMedCentral

Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704CrossRefPubMed

10.

Kowalsky SJ, Liu Z, Feist M, Berkey SE, Ma C, Ravindranathan R, Dai E, Roy EJ, Guo ZS, Bartlett DL (2018) Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade. Mol Ther 26:2476–2486CrossRefPubMedPubMedCentral

11.

Lawler SE, Speranza MC, Cho CF, Chiocca EA (2017) Oncolytic Viruses in Cancer Treatment: A Review. JAMA Oncol 3:841–849CrossRefPubMed

12.

Ledford H (2015) Cancer-fighting viruses win approval. Nature 526:622–623CrossRefPubMed

13.

Lichty BD, Breitbach CJ, Stojdl DF, Bell JC (2014) Going viral with cancer immunotherapy. Nat Rev Cancer 14:559–567CrossRefPubMed

14.

Lin C, Ren W, Luo Y, Li S, Chang Y, Li L, Xiong D, Huang X, Xu Z, Yu Z, Wang Y, Zhang J, Huang C, Xia N (2020) Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade. Cancer Immunol Res 8:632–647CrossRefPubMed

15.

Liu Z, Ravindranathan R, Kalinski P, Guo ZS, Bartlett DL (2017) Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun 8:14754CrossRefPubMedPubMedCentral

16.

Markowska A, Sajdak S, Markowska J, Huczyński A (2017) Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer. Eur J Med Chem 142:87–94CrossRefPubMed

17.

McCloskey CW, Rodriguez GM, Galpin KJC, Vanderhyden BC (2018) Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics. Cancers (Basel) 10:244CrossRefPubMed

18.

Meng J, Peng J, Feng J, Maurer J, Li X, Li Y, Yao S, Chu R, Pan X, Li J, Zhang T, Liu L, Zhang Q, Yuan Z, Bu H, Song K, Kong B (2021) Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer. J Transl Med 19:415CrossRefPubMedPubMedCentral

19.

Nakashima H, Chiocca EA (2014) Modification of HSV-1 to an oncolytic virus. Methods Mol Biol 1144:117–127CrossRefPubMed

20.

Nakashima H, Nguyen T, Kasai K, Passaro C, Ito H, Goins WF, Shaikh I, Erdelyi R, Nishihara R, Nakano I, Reardon DA, Anderson AC, Kuchroo V, Chiocca EA (2018) Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. Clin Cancer Res 24:2574–2584CrossRefPubMedPubMedCentral

21.

Passaro C, Alayo Q, De Laura I, McNulty J, Grauwet K, Ito H, Bhaskaran V, Mineo M, Lawler SE, Shah K, Speranza MC, Goins W, McLaughlin E, Fernandez S, Reardon DA, Freeman GJ, Chiocca EA, Nakashima H (2019) Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy. Clin Cancer Res 25:290–299CrossRefPubMed

22.

Reid BM, Permuth JB, Sellers TA (2017) Epidemiology of ovarian cancer: a review. Cancer Biol Med 14:9–32CrossRefPubMedPubMedCentral

23.

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV (2017) Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell 170:1109–1119CrossRefPubMedPubMedCentral

24.

Santos Apolonio J, Lima de Souza Gonçalves V, Cordeiro Santos ML, Silva Luz M, Silva Souza JV, Rocha Pinheiro SL, de Souza WR, Sande Loureiro M, de Melo FF (2021) Oncolytic virus therapy in cancer: A current review. World J Virol 10:229–255CrossRefPubMedPubMedCentral

25.

Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168:707–723CrossRefPubMedPubMedCentral

26.

Szabó E, Phillips DJ, Droste M, Marti A, Kretzschmar T, Shamshiev A, Weller M (2018) Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models. J Pharmacol Exp Ther 365:422–429CrossRefPubMed

27.

Tanoue K, Rosewell Shaw A, Watanabe N, Porter C, Rana B, Gottschalk S, Brenner M, Suzuki M (2017) Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res 77:2040–2051CrossRefPubMedPubMedCentral

28.

Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y (2006) Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Ther 13:705–714CrossRefPubMed

29.

Tian C, Liu J, Zhou H, Li J, Sun C, Zhu W, Yin Y, Li X (2021) Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody. Cancer Lett 518:49–58CrossRefPubMed

30.

Tong Y, Zhu W, Huang X, You L, Han X, Yang C, Qian W (2014) PI3K inhibitor LY294002 inhibits activation of the Akt/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus. Oncol Rep 31:1581–1588CrossRefPubMed

31.

Van Dorsten RT, Wagh K, Moore PL, Morris L (2021) Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth. Front Immunol 12:734110CrossRefPubMedPubMedCentral

32.

Wang G, Kang X, Chen KS, Jehng T, Jones L, Chen J, Huang XF, Chen SY (2020) An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat Commun 11:1395CrossRefPubMedPubMedCentral

33.

Wei SC, Duffy CR, Allison JP (2018) Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov 8:1069–1086CrossRefPubMed

34.

Yoon JH, Shin JW, Pham TH, Choi YJ, Ryu HW, Oh SR, Oh JW, Yoon DY (2020) Methyl lucidone induces apoptosis and G(2)/M phase arrest via the PI3K/Akt/NF-κB pathway in ovarian cancer cells. Pharm Biol 58:51–59CrossRefPubMed

35.

Zhang H, Li J, Li G, Wang S (2016) Effects of celastrol on enhancing apoptosis of ovarian cancer cells via the downregulation of microRNA–21 and the suppression of the PI3K/Akt–NF–κB signaling pathway in an in vitro model of ovarian carcinoma. Mol Med Rep 14:5363–5368CrossRefPubMed

36.

Zhu S, Ma AH, Zhu Z, Adib E, Rao T, Li N, Ni K, Chittepu V, Prabhala R, Garisto Risco J, Kwiatkowski D, Mouw K, Sonpavde G, Cheng F, Pan CX (2021) Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. J Immunother Cancer 9:e002917CrossRefPubMedPubMedCentral

Titel: An oncolytic herpes simplex virus type 1 strain expressing a single-chain variable region antibody fragment against PD-1 and a PI3K inhibitor synergize to elicit antitumor immunity in ovarian cancer
verfasst von: Shanying Huang
Haiyan Hu
Guoling Tang
Kai Liu
Zhihua Luo
Weiwei Zeng
Publikationsdatum: 01.04.2023
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 4/2023
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-023-05754-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Roles and mechanisms of exosomal microRNAs in viral infections

Unravelling the epidemiological diversity of Zika virus by analyzing key protein variations

Characterization of a novel mycotombus-like virus from the plant-pathogenic fungus Phoma matteucciicola

Characterization and complete genome sequence analysis of the novel phage RPZH3 infecting Ralstonia solanacearum

A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets